Get the Stockscreener App
1.05
1.87%
-0.02
After Hours:
1.06
0.01
+0.95%
X T L Biopharmaceuticals Ltd Adr stock is traded at $1.05, with a volume of 53,904.
It is down -1.87% in the last 24 hours and down -10.64% over the past month.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
See More
Previous Close:
$1.07
Open:
$1.09
24h Volume:
53,904
Relative Volume:
0.09
Market Cap:
$2.88M
Revenue:
$453.30K
Net Income/Loss:
$-1.03M
P/E Ratio:
-9.2756
EPS:
-0.1132
Net Cash Flow:
-
1W Performance:
-12.50%
1M Performance:
-10.64%
6M Performance:
-30.00%
1Y Performance:
-55.32%
1-Day Range:
$1.01
$1.13
1-Week Range:
$0.99
$1.28
52-Week Range:
$0.86
$2.5699
X T L Biopharmaceuticals Ltd Adr Stock (XTLB) Company Profile
Name
X T L Biopharmaceuticals Ltd Adr
Sector
Industry
Phone
-
Address
-
Compare XTLB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XTLB
X T L Biopharmaceuticals Ltd Adr
|
1.05 | 9.43M | 453.30K | -1.03M | 0 | -0.1132 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
X T L Biopharmaceuticals Ltd Adr Stock (XTLB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-15 | Initiated | H.C. Wainwright | Buy |
X T L Biopharmaceuticals Ltd Adr Stock (XTLB) Latest News
XTL Biopharmaceuticals Announces Board Changes Following Resignation - TipRanks
XTL Biopharmaceuticals Approves Key Resolutions at Shareholder Meeting - TipRanks
XTL Biopharmaceuticals Postpones Shareholders’ Meeting Due to Quorum Issue - TipRanks
XTL Biopharmaceuticals Announces Shareholder Meeting for Key Decisions - TipRanks
XTL Biopharmaceuticals Appoints Noam Band as CEO - TipRanks
XTL Biopharmaceuticals Enters Sublicense Agreement with Biossil - TipRanks
XTL Biopharmaceuticals Reports Financial Results Amid Regional Unrest - TipRanks
XTL Biopharmaceuticals Expands with AI Company Acquisition - TipRanks
XTL Biopharmaceuticals Confirms Board and Auditor Appointments - Investing.com
XTLB Stock Price and Chart — NASDAQ:XTLB - TradingView
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates - Yahoo Finance
List of US Companies Releasing Earnings (EPS) Today - FXLeaders
The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher - Benzinga
X T L Biopharmaceuticals Ltd Adr Stock (XTLB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):